Natera, Inc. (NTRA) 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers Natera, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Natera is a diagnostics company utilizing proprietary cell-free DNA (cfDNA) technology to provide personalized genetic testing across three primary segments: Oncology (Molecular Residual Disease monitoring), Women's Health (Non-Invasive Prenatal Testing and carrier screening), and Organ Health (transplant rejection monitoring). The company operates CLIA-certified laboratories in Austin, Texas; San Carlos, California; and Boulder, Colorado, and distributes tests globally via direct sales and a cloud-based licensing model (Constellation).
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $2,306.1 million | $1,696.9 million | +35.9% |
| Product Revenue | $2,295.8 million | $1,685.1 million | +36.2% |
| Gross Margin | $1,493.2 million (64.7%) | $1,023.2 million (60.3%) | +4.4 pts |
| Net Loss | $(208.2) million | $(190.4) million | -9.3% (wider loss) |
| Operating Cash Flow | $215.3 million | $135.7 million | +58.7% |
| Cash & Equivalents | $1,076.1 million | $945.6 million | N/A |
| Debt Outstanding | $80.3 million | $80.4 million | Flat |
| Tests Processed | ~3.53 million | ~3.06 million | +15.4% |
Note: Net loss includes $354.4 million in non-cash stock-based compensation expense.
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 36.2% increase in product revenues, attributed to higher test volumes (3.53 million tests processed) and average selling price improvements. Oncology units processed grew significantly to approximately 800,800.
- Expense Increases: Operating expenses rose sharply. Research and Development (R&D) increased 54.4% to $624.1 million, and Selling, General, and Administrative (SG&A) expenses increased 39.9% to $1.177 billion. These increases were driven by headcount growth, stock-based compensation, and legal expenses.
- Acquisition: In December 2025, Natera acquired Foresight Diagnostics, Inc. for approximately $424.5 million (including stock and contingent consideration). This added $141.1 million in goodwill and $335.3 million in developed technology intangible assets.
- Debt Management: The company redeemed its $287.5 million Convertible Senior Notes in October 2024, settling primarily via stock issuance. Current debt consists solely of a $100 million credit line with UBS, of which $80.3 million is drawn.
- Tax Benefit: A significant income tax benefit of $59.9 million was recorded in 2025, primarily due to a partial release of the valuation allowance following the Foresight acquisition.
Guidance, Outlook, Risks, and Contingencies
Outlook & Strategy: Management expects to continue incurring net losses in the near future as it invests in R&D and commercialization. The company aims to expand reimbursement for microdeletions screening (Panorama) and leverage the Foresight acquisition to enhance its oncology portfolio, particularly in lymphoma and phased variant detection.
Key Risks:
- Reimbursement: Significant reliance on third-party payers. Low reimbursement rates for microdeletions screening persist, and changes in Medicare/Medicaid policies or PAMA rate implementations could negatively impact revenue.
- Regulatory: Uncertainty regarding FDA regulation of Laboratory Developed Tests (LDTs). While a 2024 FDA rule was vacated by a court in 2025, legislative efforts (VALID Act) continue, which could impose premarket approval requirements.
- Supply Chain: Reliance on sole suppliers for critical components, specifically Illumina for sequencers/reagents and Streck for blood collection tubes.
- Legal Proceedings: The company faces significant litigation risks, including a $292.5 million jury verdict in a false advertising case against Guardant Health (appeal pending) and a $57 million verdict in a patent infringement case against Ravgen (appeal pending). Total legal accruals as of year-end were approximately $32.6 million.
Investor Verification Checklist
- Reimbursement Rates: Verify the actual reimbursement rates received for Panorama microdeletions testing versus the CPT code benchmarks, as this is a stated constraint on revenue growth.
- Legal Exposure: Monitor the status of the Guardant Health and Ravgen litigation appeals, as unfavorable outcomes could result in substantial cash outflows or operational restrictions.
- Acquisition Integration: Assess the integration progress of Foresight Diagnostics and the likelihood of achieving the milestones required for the $175 million contingent consideration payment.
- Regulatory Landscape: Track legislative developments regarding the VALID Act and FDA enforcement discretion over LDTs, as a shift to premarket approval could delay product launches and increase costs.
- Supplier Concentration: Confirm the status of supply agreements with Illumina and Streck, given the lack of validated alternative platforms for key tests.